This only supports IE 8 and later, so browse at your own risk or upgrade. Internet Explorer: IE8 以 推 奨 そ れ 以前 ウ ザ を ご 使用 ブ 方 最 方 最 最 版 に プ グ て く だ さ。
M / CLOUDED
New coronavirus vaccines are a must for the prolonged launch of the Tokyo Olympic and Paralympic Games in less than a year, but several studies show that other people inflamed with COVID-19 have lost their immunity to infection within a few months, overesusing Japan’s hopes of giving its battered economy a much-needed touch.
Studies have shed bloodless water on the optimism of vaccine brands working tirelessly to produce massive vaccines that stimulate antibodies in others who oppose the disease.
Still, experts say it may not be as bad as it sounds. An examination through King’s College London of more than 90 people inflamed with COVID-19 showed that antibody levels peaked 3 weeks after the onset of symptoms and then decreased rapidly. approximately 16. 7% of them had maximum levels of antibodies 3 months later. Similar effects have also been reported in Spain.
“The degrees of antibodies for asymptomatic Americans are low and antibodies in others without symptoms or mild symptoms do not last long,” said Dr. Tetsuo Nakayama, an assigned professor at the Kitasate Institute of Life Sciences and director of the Japanese Society of Clinical Virology.
Dr. Barry Bloom, a professor at Harvard School of Public Health, says knowledge from many countries implies that anti-SARS-CoV-2 antibodies in patients tend to be minimized faster than in other viral infections. “In fact, they last several months, and some can last much longer. “
For the world’s first outbreak of Severe Acute Respiratory Syndrome (SARS) in 2002-2003, other people had antibodies 18 years later, Bloom added.
It is still known which point of antibodies is sufficient to provide protection, but even a small amount of neutralizing antibodies can be protective, Bloom said.
The scenario doesn’t seem as serious as many worry about our resistant immune formula made up of T cells in the blood that join and kill swollen cells, B cells that produce antibodies, depending on the reminiscence of beyond infections.
“T cells bring immune reminiscence and the reintroduction of the virus can simply stimulate a reminiscence reaction that leads to immediate antibody production,” Bloom said.
There are many questions about the efficacy and efficacy of vaccines in the prevention of coronavirus disease, however, a team of scientists at the University of Oxford said the effects of Phase I-2 trials showed that the vaccine being developed by British biopharmaceutical AstraZeneca has caused a T-cell reaction within 14 days of vaccination and reaction of antibodies within 28 days.
“We saw the most powerful immune reaction in the 10 participants who won two doses of the vaccine, indicating that this is a smart vaccination strategy,” said Professor Andrew Pollard, the study’s leading researcher. COVID-19 vaccine from the University of Oxford.
Vaccines were expected to pave the way for the world economy and Japan to host the Olympic Games next year, Nakayama said, but this is not easy to achieve in such a short era because long-term follow-up studies are needed to see if other people who have won the disease vaccines have severe symptoms of COVID-19 a few years later.
“Successful antibody creation through a vaccine booster injection and side effect reports are not enough to provide convenience,” he said.
Customers for good luck at the Tokyo Olympics have the vaccines, but it’s unclear how long it would take brands to manufacture the five billion doses for everyone at risk in the world, Bloom said.
“It is expected that the pandemic will disappear during the summer of 2021, but that is not certain at this time,” he added.
A ray of hope for Tokyo is news of Russia’s approval of the world’s first vaccine opposed to the new coronavirus, which could bring the progression of many other vaccines around the world to life. However, the Moscow resolution surprised everyone when the approval came “un completed. “rigorous testing of protection and effectiveness,” Bloom added.
“There is a fear that the Russian government has approved a vaccine without the mandatory verification knowledge to get there first,” he said. “It is a recombinant of two adenovirus strains, so there is no explanation why it might not be effective and safe,” however, genuine knowledge is desired. ‘
Since the early stages of the COVID-19 crisis, the Japan Times has provided free access to very important data on the effect of the new coronavirus, as well as practical data on how to deal with the pandemic. today so that we can continue to provide you with up-to-date and detailed data on Japan.
The Japan Times LTD. All rights are reserved.